Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
CD19 Expressing Malignancies|Hematologic Malignancy
GENETIC: PBCAR19B
Maximum Tolerated Dose (MTD), To determine the maximum tolerated dose (MTD), Day 1 - Day 28|Number of participants with Dose Limiting Toxicity(ies), To assess adverse events as dose limiting toxicities as defined by the protocol and CTCAE v5.0., 1 year
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.